MedTrace Logo

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

NCT04741828 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2025-06-03

No results posted yet for this study

Summary

Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.

Conditions

  • Vaccine

Interventions

DRUG

Vi-DT Typhoid Conjugate Vaccine

Typhoid Conjugate Vaccine

Sponsors & Collaborators

  • Indonesia University

    collaborator OTHER

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Bernie E Medise, MD · Department of Child Health, School of Medicine, University of Indonesia

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2024-10-28
Completion
2024-12-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04741828 on ClinicalTrials.gov